Juniper Pharmaceuticals

Juniper Pharmaceuticals- Developing proprietary products- Developing therapies for the treatment of unmet medical needs in women’s health. Juniper’s pipeline will leverage the 505(b)(2) regulatory pathway with new formulations of existing pharmaceuticals. Juniper Pharma Services- A CDMO taking a science-led approach to deliver rapid, right first time, products for our customers. Our philosophy is to use an interdisciplinary team to deliver the simplest or the toughest CMC requirements for clinical trials. This approach ensures R&D hurdles are rapidly overcome, timelines are met and budget creep curtailed. The fundamentals of science-led delivery derives from nearly two decades of continuing experience helping pharmaceutical companies to investigate, understand and resolve some of the toughest development challenges and also provide this expertise in block buster patent litigation proceedings. From our 40,000 sq ft GMP facility in Nottingham, UK, we flexibly guide our customers along the right pathway for delivering robust products, whether that can be achieved via conventional pharmaceutics or enabled formulations (spray drying, HME, solid dispersions, SEDDs/SMEDDs, etc.). We are known for our ability to work with challenging drug substance properties or specialised delivery regimens for oral or topical products. Juniper Pharma Services’ offering spans from pre-clinical assessment to clinical trial manufacturing including; • Preformulation, materials characterisation and compatibility studies. • Solid form selection and stability studies. • Screening for formulation development • Analytical method development • Formulation development and tox formulations • Clinical development • Clinical Trial Manufacturing • QC release (QP release where relevant) • Stability testing